The IAB TSO 500 represents a powerful assay enabling the genomic profiling of DNA (523 genes) and RNA (55 genes) variants implicated in various tumor types. Various biomarkers (SNVs, indels, fusions, splice variants, TMB, MSI) corresponding to a given tumor type can be in parallel evaluated from the same sample. The IAB TSO 500 sequencing service offers a high-quality and affordability results generated by using TruSight Oncology 500 panel, Illumina and sequencing platform NextSeq 500, Illumina The data analysis and interpretation followed by rapid clinical validation are powered by PierianDx software and expert bioinformatics services.

The experienced team strictly follows IAB TSO 500 workflow to perform the essential QC steps on your samples and generate reliable and reproducible results. A customized workflow is available.

Sample requirement

  • Human DNA/RNA solid or liquid biopsy samples (including FFPE samples)
  • RNA/DNA concentration: ≥ 5 ng/µl
  • Minimum sample volume: 20 µl

Kit for library preparation

  • TruSight Oncology 500 panel (Illumina)
  • relevant DNA/RNA variants in various tumor types
  • targeting 523 genes (55 RNA genes)
  • 1.94 Mb panel including MSI and TMB biomarkers 
  • analytical specificity >99,99%


    • NextSeq 500, High Output (Illumina)
    • Pair-end sequencing 2×150 bp
    • Internal standard – PhiX Spike-in
  • BaseSpace Sequencing Hub for data storage and sharing 

Data QC 

  • Guaranteed Phred Q30 > 80% bases (sequencing mode 2x100bp)
  • IAB recommends a minimum of 80 M/DNA a 20 M/RNA reads per sample

Bioinformatic analysis

  • Quality control and data filtering
  • DNA-seq Analysis Somatic Variants
  • Tumor Burden Mutation and MSI
  • RNA-Seq Gene fusions
  • PierianDX – Complete clinical genomic solution

Delivery time

  • 8 weeks since sample delivery to the data output
  • accelerated service on request wofkova@iabio.eu


  • ČSN EN ISO 9001:2016
  • ČSN EN ISO 13485 ed. 2:2016